Simoni G, Gianotti A, Ardia A, Baiardi A, Civalleri D
Clinica Chirurgica B, University of Genoa, Italy.
Cardiovasc Drugs Ther. 1995 Apr;9(2):347-50. doi: 10.1007/BF00878680.
Plasma levels of lipoprotein-a [Lp(a)] > 30 mg/dl represent an independent risk factor for cardiovascular diseases with both proatherosclerotic and prothrombotic activity. The results of dietary or pharmacological treatment are not encouraging and are often controversial. We have evaluated a combination of medical treatment with Gemfibrozil (600 mg bid) and a Mediterranean diet for 2 months in 15 patients with both hypercholesterolemia (> 240 mg/dl) and high levels of Lp(a) (> 30 mg/dl). Three patients dropped out within the first 2 weeks, complaining of epigastric pain and burning; the remainder (5 females and 7 males, mean age 70 years) completed the treatment without any side effects. The median values of Lp(a) decreased from 36.5 to 8.4 mg/dl (p < 0.0002) and total cholesterol from 254.5 to 208.0 mg/dl (p < 0.0001). The small number of patients does not permit any definitive conclusion on effectiveness to be drawn, but the results indicate further randomized studies might prove worthwhile.
脂蛋白-a [Lp(a)] 的血浆水平 > 30 mg/dl 是心血管疾病的独立危险因素，具有促动脉粥样硬化和促血栓形成活性。饮食或药物治疗的结果并不令人鼓舞，且常常存在争议。我们对15例同时患有高胆固醇血症（> 240 mg/dl）和高水平Lp(a)（> 30 mg/dl）的患者进行了为期2个月的治疗评估，采用吉非贝齐（600 mg，每日两次）药物治疗与地中海饮食相结合的方法。3例患者在最初2周内退出，抱怨上腹部疼痛和烧灼感；其余患者（5名女性和7名男性，平均年龄70岁）完成了治疗，且无任何副作用。Lp(a) 的中位数从36.5降至8.4 mg/dl（p < 0.0002），总胆固醇从254.5降至208.0 mg/dl（p < 0.0001）。患者数量较少，无法得出关于有效性的任何确定性结论，但结果表明进一步的随机研究可能是值得的。
